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The role of nicotine in metastasis and anticancer drug 
resistance of head and neck squamous cell carcinoma  
RIEKO SHIMIZU 
 
以下は, INTERNATIONAL JOURNAL OF ONCOLOGY54:283-294.2019 を改変したものである.
Abstract. Epidermal growth factor (EGF) is overexpressed in 
many cancers and is associated with worse prognosis. EGF 
binds to its cell surface receptor (EGFR), which induces 
EGFR phosphorylation. Phosphorylated EGFR (p-EGFR) is 
translocated into the nucleus, which increases cancer cell 
activity. Nicotine, which is one of the main components of 
tobacco, is absorbed through pulmonary alveoli and mucosal 
epithelia in the head and neck region by smoking and moves 
into the blood. Nicotine in blood binds to nicotinic acetyl- 
choline receptor (nAChR) in the central nervous system and 
serves a crucial role in tobacco addiction. Although nAChR 
localization is thought to be limited in the nervous system, 
nAChR is present in a wide variety of non-neuronal cells, 
including cancer cells. Recent studies suggest that nicotine 
contributes to the metastasis and resistance to anti-cancer 
drugs of various cancer cells. However, it remains unknown 
whether head and neck squamous cell carcinoma (HNSCC) 
cells can utilize nicotine-nAChR signaling to metastasize 
and acquire resistance to anti-cancer drugs, even though the 
mucosal epithelia of the head and neck region are the primary 
sites of exposure to tobacco smoke. To the best of our knowl- 
edge, the present study is the first to demonstrate the role of 
nicotine in metastasis and anti-EGFR-therapy resistance of 
HNSCC. The present findings demonstrated that nicotine 
increased proliferation, migration and invasion in HNSCC 
cells. It was also demonstrated that nicotine restored 
cetuximab- inhibited proliferation, migration and invasion of 
HNSCC cells. Finally, an in vivo experiment revealed that 
nicotine increased lymph node metastasis of xenografted 
tumors, whereas an nAChR inhibitor suppressed lymph node 
metastasis and p-EGFR nuclear localization of xenografted 
tumors. Taken together, these results demonstrated that 
nicotine induced nuclear accumulation of p-EGFR. These 
signaling pathways elevated the activities of HNSCC cells, 
causing lymph node metastasis and serving a role in cetuximab 
resistance. 
 
Introduction 
 
Epidermal growth factor (EGF) was isolated from mouse 
submaxillary glands and demonstrated to promote incisor 
eruption and eyelid opening in newborn rodents (1). After 
EGF binds to its cell surface receptor (EGFR), EGFR 
undergoes dimerization, which in turn induces EGFR 
auto-phosphorylation (2). This auto-phosphorylation elicits 
downstream signal transduction cascades such as the 
phosphoinositide 3-kinase-pyruvate dehydrogenase kinase-
protein kinase B (Akt) and RAF-mitogen-activated protein 
kinase kinase-extracellular signal-regulated kinase pathways, 
which promote cell survival and proliferation. Phosphorylated 
(p-) EGFR is translocated to the cytoplasm and degraded in 
lysosomes, which causes suppression of downstream sig-
naling cascades in normal cells (2). However, in cancer cells, 
p-EGFR is accumulated in the nucleus, increasing cancer cell 
activity (3). EGFR is overexpressed in many cancers, 
including head and neck, breast, lung, colon, stomach, kidney, 
prostate and ovarian cancer, and is associated with worse 
outcome (4-6). An anti-EGFR monoclonal antibody, cetu-
ximab, is the first molecular target drug for head and neck 
squamous cell carcinoma (HNSCC) (7,8). When combined 
with radiotherapy and chemotherapy, cetuximab has been 
demonstrated to have significant survival benefits in patients 
with locally advanced and recurrent/metastatic HNSCC, res-
pectively (7,8). However, resistance to cetuximab is known to 
develop gradually (9), and presents an important challenge for 
the future. 
Tobacco smoking is associated with the carcinogenesis and 
development of cancer (10). Tobacco smoking is carcinogenic 
to the oral cavity, pharynx, larynx, esophagus, stomach, colon, 
liver, pancreas, lung, uterine cervix, ovary, kidney, renal pelvis 
and ureter, and bladder (10). The organs directly exposed to 
tobacco smoke are at high risk. Tobacco smoke is divided into 
a particle and gas phase (11). The particle phase includes tar 
and nicotine, while the gas phase includes carbon monoxide. 
Tar contains many carcinogenic chemicals, including benzo- 
pyrene and nitrosamine. Nicotine is responsible for tobacco 
addiction, and thus nicotine replacement therapy, which 
supplies nicotine in the form of gum or a patch, is used to help 
individuals with tobacco addiction quit smoking (12). 
The nicotine in the tobacco smoke is absorbed across the 
epithelium of the lung, and the mucosal epithelia in the head 
and neck region, e.g., the oral cavity, nasal cavity, pharynx, 
nasopharynx and larynx (13). Nicotine exerts its cellular func- 
tions through nicotinic acetylcholine receptors (nAChRs). 
nAChRs are homomeric or heteromeric pentameric proteins 
consisting of α1-10, β1-4, γ, δ and ε subunits, and are located in 
the central nervous system and neuromuscular junctions (14). 
The binding of nicotine to nAChRs in the ventral tegmental 
area of the midbrain induces the release of dopamine to the 
nucleus accumbens, which is involved in the rewarding 
effects of nicotine and nicotine addiction. Although nAChR 
localization is thought to be limited in the nervous system, 
nAChR is present in a wide variety of non-neuronal cells, 
including bronchial epithelial, urothelial, skin, endothelial and 
vascular smooth muscle cells (15). The mucosal epithelia of 
the head and neck region are the primary sites of exposure to 
tobacco smoke, and nAChRs have been observed in mucosal 
epithelial cells in these regions (16,17). Previous studies have 
suggested that nAChRs are also present in lung cancer, breast 
cancer, pancreatic cancer, colon cancer and head and neck 
cancer cells (15,18-21). In lung and breast cancer, nicotine 
has been demonstrated to contribute to tumor growth and 
metastasis (19,20). Nicotine also controls the expression and 
subcellular localization of EGFR in breast cancer cells (22). 
Specifically, nicotine decreases the expression of EGFR, and 
enhances the accumulation of p-EGFR in the nucleus, thereby 
increasing proliferation of breast cancer cells (22). Finally, 
in lung cancer cells, nicotine serves a role in the resistance 
against EGFR inhibitors (23,24). 
These facts prompted us to explore whether HNSCC 
cells could utilize nicotine-nAChR signaling to metastasize 
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from the primary tumor to the regional lymph nodes and 
acquire resistance to cetuximab through EGFR activation. 
In the present study it was demonstrated that nicotine 
increased proliferation, migration, invasion, p-EGFR nuclear 
trans-location in HNSCC cells. It was also demonstrated that 
nicotine restored cetuximab-inhibited proliferation, mig-
ration and invasion of HNSCC cells. Finally, it was demon-
strated that an nAChR inhibitor suppressed lymph node 
metastasis in a mouse model of lymph node metastasis using 
OSC-19 cells. 
 
Materials and methods 
 
Cell culture and reagents. The following human HNSCC 
cell lines were used in the present experiments: HSC-2, a 
mouth floor SCC cell line derived from a metastatic cervical 
lymph node; HSC-3, a tongue SCC cell line derived from a 
metastatic cervical lymph node; OSC-19, a tongue SCC cell 
line derived from the primary site; and OSC-20, a tongue 
SCC cell line derived from a metastatic cervical lymph node. 
HSC-2 and HSC-3 were obtained from the Cell Engineering 
Division of the RIKEN BioResource Center (Ibaraki, 
Japan). OSC-19 and OSC-20 were obtained from the Health 
Science Research Resources Bank (Osaka, Japan). Human 
umbilical vein endothelial cells (HUVECs) were purchased 
from Takara Bio, Inc. (Otsu, Japan). All cancer cells were 
cultured in Dulbecco's modified Eagle's medium/Ham's 
F-12 nutrient mixture (DMEM/F-12: Gibco; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) supplemented with 
10% fetal bovine serum (FBS: Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) at 37˚C. HUVECs were cultured in 
endothelial cell growth medium-2 (Takara Bio, Inc.) at 37˚C. 
Nicotine (Sigma-Aldrich; Merck KGaA; 0.5 µM) (19,20,22), 
mecamylamine hydrochloride (MCA; Sigma-Aldrich; Merck 
KGaA; 50 nM) (22), α-bungarotoxin (α-BTX; Abcam, 
Cambridge, UK; 1 µM) (17) and cetuximab (Merck 
KGaA;0.5 µg/ml) (27) were purchased. The concentration of  
nicotine (0.5 µM) used was decided based on previously 
published basic studies (19,20,22) and clinical investigations 
in which the concentrations of nicotine in the bloodstream of 
smokers exposed to nicotine at pharmacological 
concentrations were reported to be 0.09-1 µM (25,26). 
 
Cell proliferation. Cells were seeded at a density of 1x105 cells 
in a 6-well plate. After becoming subconfluent at 37˚C, the 
cells were cultured for 24 h in DMEM/F-12 without FBS. 
They were then cultured in the presence or absence of nicotine 
(0.5 µM) (19,20,22), MCA (50 nM) (22), α-BTX (1 µM) (17) 
or cetuximab (0.5 µg/ml) (27) in DMEM/F-12 supplemented 
with 0.5% FBS. The number of cells was counted with 
TC10TM automated cell counter (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) after 5 days. 
 
Invasion and migration assays. Invasion and migration of 
cells were studied as reported previously, by using Boyden 
cham- bers with or without Matrigel®, respectively (BD 
Biosciences, 
Franklin Lakes, NJ, USA) (28). Cells in the logarithmic 
growth phase were detached by trypsin-EDTA, and 3x104 
cells in serum-free DMEM/F12 were added to 
polycarbonate membranes (pore size, 8.0 µm). Nicotine (0.5 
µM) was added to the lower chamber, and the system was 
incubated at 37˚C for 24 h in 5% CO2. Following incubation 
and fixation with 70% ethanol for 10 min at room temperature, 
the non-invading or migrating cells were removed with a 
cotton swab  and the remaining cells were stained with 
2% crystal violet (Sigma-Aldrich; Merck KGaA) for 5 min 
at room temperature. The number of stained cells on the lower 
side of the membrane in 4 light microscopic fields were 
counted, and the mean value of 3 wells was determined. 
 
Immunoblot analysis. HUVEC, HSC-2, HSC-3, OSC-19 and 
OSC-20 cells in monolayer cultures were rinsed with ice-cold 
PBS and lysed in an ice-cold lysisbuffer (50mM Tris-HCL, 
pH7.4, containing 150mM NaCl, 1% Triton X-100, 1% NP-
40, 10mM NaF, 100mM leupeptin, 2mg/ml aprotinin and 
1mM phenylmethyl sulfonyl fluoride). Protein concentration 
was determined using a BCA Protein Assay Kit (Pierce, 
Thermo Fisher Scientific, Inc.) The cell lysates containing 10 
µg total protein in the lysis buffer were electrophoresed in 
12% SDS-PAGE gels, and the proteins were then transferred 
to nylon membranes (Immobilon-P; EMD Millipore, 
Billerica, MA, USA). The membranes were blocked with 2% 
non-fat dry milk in TBS at 4˚C for 1h and then incubated with 
a 1:400 dilution of rabbit anti-human α7 nAChR polyclonal 
IgG (ab10096; Abcam) and with a 1:1,000 dilution of mouse 
anti-humanβ-actin monoclonal IgG (ab49900) overnight at 
4˚C. Horseradish peroxidase (HRP)-conjugated goat anti-
rabbit (RPN4301) or sheep anti-mouse IgG (NA931) were 
used as the secondary antibody at a 1:1,000 dilution (GE 
Healthcare Life Sciences, Little Chalfont, UK). Bands were 
visualized via enhanced chemiluminescence (RPN2109; GE 
Healthcare Life Sciences). 
  
Lymph node metastasis model. All animal experiments 
were approved by the Institutional Animal Care and Use 
Committee of Okayama University (Okayama, Japan; 
OKU-2016046). The lymph node metastasis model was 
prepared as described previously (29). A total of 50 male 
athymic mice (nu/nu; age, 5 weeks; mean body weight,19.5 
g) were obtained from CLEA Japan, Inc. (Tokyo, Japan). 
OSC-19 cells, 8x105 per mouse, were inoculated into a hind 
footpad. Groups of 10 mice each were peritone- ally injected 
with either PBS, nicotine (30 µg/mouse) (20), MCA (20 
µg/mouse) (30), nicotine and MCA, cetuximab (1 
mg/mouse) (31), or cetuximab and nicotine every day. 
Tumor sizes and body weights were measured weekly, and 
the former were recorded in mm3 (length x width2 / 2). Mice 
were sacrificed at day 42, the footpad tumor tissues and 
popliteal lymph nodes were isolated and slides were prepared 
as described previously (29). 
 
Immunohistochemistry for xenograft tumor specimens. 
Paraffin  blocks  of  specimens  were  cut  at  4 -µm  
thickness. The sections were deparaffinized, and  then  
autoclaved in 0.2% citrate buffer for 15 min for antigen 
retrieval. Sections were incubated with 3% hydrogen  
peroxide for 30 min at room temperature to block 
endogenous peroxidase activity. Immunohistochemistry 
was performed using rabbit anti-human EGFR monoclonal 
IgG (Cell Signaling Technology, Inc.) and rabbit anti-human 
p-EGFR monoclonal IgG (Abcam), each at 1:100 dilution. 
The sections were incubated with the primary antibodies 
at 4˚C for 16 h, and then treated with Envision System 
Labeled Polymer (Dako; Agilent Technologies, Inc., Santa 
Clara, CA, USA) for 60 min at a dilution of 1:100. The 
immunoreaction was visualized using a 3,3'-
diaminobenzidine substrate-chromogen solution. Finally, the 
sections were immersed in an ethanol and xylene bath and 
mounted for examination. The extent of p-EGFR staining 
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was evaluated according to the percentage of cells with 
strongly stained nuclei in 3 visual fields under a light 
microscope (x200). All immunohistochemistry studies were 
evaluated by 2 experienced observers who were blind to the 
conditions of the experiments as reported previously (32). 
Statistical analysis. Data were analyzed by using unpaired 
Student's t-test for analyses between two groups, and one-
way analysis of variance with Bonferroni post hoc tests for 
the analysis of multiple group comparisons using SPSS 
statistical software (version 22; IBM Corp., Armonk, NY, 
USA). Results were expressed as the mean ± standard 
deviation. To control for multiple testing for data in the 
incidence of popliteal lymph node metastasis in mice, q-values 
were calculated with the false discovery rate method 
controlled by the Benjamini-Hochberg procedure. P<0.05 
and q<0.05 were considered to indicate statistically 
significant differences.
 
 
 
Figure 1. Effects of nicotine on the cell proliferation and expression of α7 nAChR of head and neck squamous cell carcinoma cells. Expression of α7 nAChR in 
HSC-2, HSC-3, OSC-19 and OSC-20 cells. HUVECs were used as a positive control of α7 nAChR. Data are presented as the mean ± standard deviation of 
triplicates from a typical experiment. *P<0.05. nAChR, nicotinic acetylcholine receptor; DMEM/F-12, Dulbecco's modified Eagle's medium/Ham's F-12 nutrient 
mixture; FBS, fetal bovine serum; HUVEC, human umbilical vein endothelial cell.
Results 
 
Nicotine receptor was expressed in HNSCC cells. It is 
that Nicotine is known to exert its cellular functions 
through nicotinic acetylcholine receptors (nAChRs), 
whether nicotine receptors were expressed in HNSCC cells 
was firstly examined. Among nicotinic acetylcholine 
receptors, α7 nAChR has been reported as the primary 
receptor that mediates the proliferative effects of 
nicotine in various cancer cells (18). In the present study, 
it was demonstrated that all four HNSCC cell lines 
exhibited stronger α7 nAChR expression than that of the 
HUVEC used as the positive control for α7 nAChR (Fig. 
1). 
 
Nicotine upregulated cell activities and nAChR 
inhibitors  suppressed the effects of nicotine in 
HNSCC cells. The effects of nicotine and nAChR 
inhibitorson HNSCC cells were evaluated. As HSC-3 and 
OSC-19 have been reported to metastasize to the lymph 
nodes (33,34), it was decided to use these cell lines in later 
experiments. HSC-3 and OSC-19 were treated with MCA 
(a non-selective nAChR inhibitor) and α-BTX (an α7 
nAChR inhibitor) in the presence of nicotine. Nicotine 
increased cell viability 1.3-fold in both HSC-3 and OSC-
19 cells. MCA and α-BTX inhibited nicotine-induced 
viability to the same level as in the control group (Fig. 2A). 
In regard to cell migration, nicotine increased cell 
migration 1.4- and 1.2-fold in HSC-3 and OSC-19 cells, 
respectively, and MCA and α-BTX suppressed these 
nicotine-induced effects (Fig. 2B). Finally, invasion of 
HSC-3 and OSC-19 cells was increased 1.4- and 1.3-fold 
by nicotine, respectively, and MCA and α-BTX   
counteracted these effects as well (Fig. 2C). 
 
 
 
Nicotine counteracted the anti-tumor effects of cetuximab 
in HNSCC cells. Nicotine contributes to resistance to 
anti-cancer drugs of various cancer cells. In lung cancer 
cells, nicotine serves a role in the resistance against EGFR 
inhibitors. it was speculated that Cancer cells can utilize 
nicotine-nAChR signaling to acquire resi-stance to 
cetuximab, which is first molecular target drug for HNSCC. 
Cetuximab-induced skin reactions are suppressed by 
cigarette smoking in patients with advanced colorectal 
cancer. To test this hypothesis, HNSCC cells were treated 
with cetuximab and nicotine, then the cell activities were 
evaluated. In the presence of cetuximab alone, the 
proliferation of HSC-3 and OSC-19 cells was significantly 
inhibited. When nicotine was added, however, the 
proliferation of both HSC-3 and OSC-19 cells increased to 
1.4-fold of that in the group treated with cetuximab alone 
(Fig. 3A). Cetuximab also signif- icantly inhibited the cell 
migration of HNSCC cells. However, when nicotine was 
added, the cell migrations of HSC-3 and OSC-19 cells were 
increased to 1.7- and 1.3-fold of those in the cells treated 
with cetuximab alone (Fig. 3B). In a similar manner, the 
levels of invasion of HSC-3 and OSC-19 cells treated with 
cetuximab and nicotine were 1.9- and 1.6-fold of those in 
the cells treated with cetuximab alone, respectively. 
 
An nAChR inhibitor suppressed the tumor growth and 
lymph node metastasis of xenografted HNSCC in athymic 
mice. To further investigate whether nicotine was 
responsible for tumor growth and metastasis by HNSCC 
cells, an animal model of lymph node metastasis was 
utilized (29). To inhibit nAChRs, only MCA was used in 
animal experiments. MCA (35) is well-known as an 
antihypertensive drug under the name Inversine® (36), 
whereas α-BTX is famous as a snake venom (37); therefore, 
MCA was speculated to be more suit- able for future 
clinical application. 
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Figure 2. Effects of nicotine and nAChR inhibitors on the cell viability, migration and invasion of HNSCC cells. (A) Viability. Cells were seeded at a density of 
1x105 cells in a 6 -well plate. After becoming subconfluent, cells were cultured for 24 h in DMEM/F-12 without FBS. They were then cultured in the presence or 
absence of nicotine, MCA or α-BTX in DMEM/F-12 supplemented with 0.5% FBS. The cell number was measured at day 5. (B) Migration. Migration was 
evaluated using Boyden chambers. Cells were seeded at a density of 3x104 in medium with or without MCA, α-BTX or cetuximab on polycarbonate membranes. 
Nicotine was added to the lower chamber, and the system was incubated for 24 h. Following incubation, the number of cells on the lower side of the membrane 
was counted. (C) Invasion. Invasion was evaluated using Boyden chambers with Matrigel®. Incubation and cell counting were performed as in the migration 
assay. All experiments were repeated 3 times. Data are presented as the mean ± standard deviation of triplicates from a typical experiment. *P<0.05. nAChR, 
nicotinic acetylcholine receptor; HNSCC, head and neck squamous cell carcinoma; DMEM/F-12, Dulbecco's modified Eagle's medium/Ham's F-12 nutrient 
mixture; FBS, fetal bovine serum; MCA, mecamylamine hydrochloride; α-BTX, α-bungarotoxin.
In the animal experiments, nicotine increased the growth 
rate of xenografted tumors compared with the rate in the 
control group, and MCA decreased tumor growth compared 
with the nicotine-treated group (Fig. 4A). The tumor volumes 
at the end of the experiment (day 42) for the control group, 
nicotine-treated group and MCA group were 615.2±65.3, 
950.0±188.9 and 686.5±156.4 mm3, respectively. These results 
indicated an ~54.5% increase in the tumor growth rate for 
the nicotine-treated group. The findings also suggested that 
MCA effectively inhibited the nicotine-induced xenograft 
tumor growth of HNSCC cells in athymic mice to the same 
level as in the control group (Fig. 4A). Furthermore, nicotine 
increased cetuximab-suppressed xenografted tumor growth 
from 1.2±1.8 to 32.9±37.7 mm3, suggesting that nicotine may 
contribute to local relapse following anti-EGFR therapy. 
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Figure 3. Effects of nicotine on cetuximab-suppressed viability, migration and invasion of head and neck squamous cell carcinoma cells. (A) Viability. Cells 
were seeded at a density of 1x105 cells in a 6 -well plate. After becoming subconfluent, cells were cultured for 24 h in Dulbecco's modified Eagle's 
medium/Ham's F-12 nutrient mixture without fetal bovine serum. They were treated with cetuximab for 30 min, and then cultured in the presence or absence of 
nicotine. The cell number was measured at day 6. (B) Migration. Migration was evaluated using Boyden chambers. Cells were seeded at a density of 3x104 in 
medium with cetuximab on polycarbonate membranes. Nicotine was added to the lower chamber, and the system was incubated for 24 h. Following incubation, 
the number of cells on the lower side of the membrane was counted. (C) Invasion. Invasion was evaluated using Boyden chambers with Matrigel®. Incubation 
and cell counting were performed as in the migration assay. All experiments were repeated 3 times. Data are presented as the mean ± standard deviation of 
triplicates from a typical experiment. *P<0.05. 
To determine whether nicotine influences p-EGFR local- 
ization in vivo, the percentage of p-EGFR-positive nuclei in the 
tumor specimens was evaluated. As presented in Fig. 4B, the 
percentage of p-EGFR-positive nuclei was increased in the 
nicotine-treated group (57.7±8.4%) compared with the 
control group (42.6±9.9%), which was consistent with the in 
vitro analysis. Conversely, MCA decreased the percentage of p-
EGFR-positive nuclei to the level of the control group 
(46.8±9.6%). Nicotine also increased the rate of popliteal lymph 
node metastasis from 10 to 60%. MCA decreased the rate of 
metastasis to 20%. Although there were no significant differ- 
ences between the any two groups, there was a trend toward 
higher metastasis rate with nicotine compared with control. 
(control vs. nicotine, q=0.057; nicotine vs. nicotine+MCA, 
q=0.159; nicotine+MCA vs. control, q=1.593; Fig. 4C). There 
was no lymph node metastasis in either the cetuximab-treated 
group or the cetuximab and nicotine-treated group.Taken 
together, the in vivo experiments revealed that nicotine 
increased the tumor growth and lymph node metastasis of 
HNSCC, whereas MCA suppressed them. It was also 
demonstrated that nicotine restored the cetuximab-inhibited 
tumor growth of HNSCC. The activation and nuclear 
localization of EGFR may contribute to these tumor-
promoting effects of nicotine. 
 
Discussion 
 
Nicotine, one of the crucial components in the addictiveness 
of tobacco, also has important roles in the invasion and 
metastasis of various cancers, including lung cancer, breast 
cancer, glioma, bladder cancer, pheochromocytoma and 
colorectal cancer (15,18). In lung cancer cells nicotine exposure 
 6 
          
 
Figure 4. Effect of nicotine, MCA and cetuximab on the growth of OSC-19 xenografts and lymph node metastasis in athymic mice. (A) A total of 8x105 OSC-19 
cells per mouse (10 mice/group) were inoculated into the hind footpad of athymic mice. Mice were peritoneally administered with PBS, nicotine (30 µg/mouse), 
MCA (20 µg/mouse), nicotine and MCA, cetuximab (1 mg/mouse), or cetuximab and nicotine every day.  Mice were sacrificed at day 42. In bar chart, the  
data are presented as tumor volume in mm3 (length x width2 / 2). Data are presented as the mean ± standard deviation. *P<0.05. (B) IHC staining of OSC-19 
xenograft tumor specimens from the hind footpad. IHC staining of EGFR and p-EGFR in tumors from the OSC-19 treated with or without nicotine or MCA is 
presented. Nicotine induced nuclear localization of p-EGFR (arrows) whereas MCA suppressed nicotine-induced nuclear localization of p-EGFR. Scale bar, 100 
µm. (C) The rate of popliteal lymph node metastasis is presented as the number of mice with metastases/number of mice injected. Lymph node metastasis was 
observed in the control group (10%), nicotine-treated group (60%) and nicotine and MCA-treated group (20%). MCA, mecamylamine hydrochloride; IHC, 
immunohistochemical; EGFR, epidermal growth factor receptor; p, phosphorylated.
induces epithelial-mesenchymal transition (38). In breast 
cancer cells, nicotine promotes cell motility via PKC and 
cdc42, leading to lung metastasis (20). However, its effect in 
HNSCC cells is unknown. To determine whether nicotine 
influences HNSCC in vivo, a mouse model of lymphatic 
metastasis was prepared (29). In this model, nicotine 
increased the tumor volume and incidence of metastasis in 
regional lymph nodes compared with the control groups. 
Consistent with the in vivo experiments, in in vitro studies, cell 
proliferation, migration and invasion were significantly 
elevated in the nicotine-treated groups than the control groups 
in all four HNSCC cell lines. In the animal model, nicotine 
failed to induce lymphangiogenesis in tumor tissues (data not 
shown). This suggests that nicotine-induced lymphatic 
metastasis was attributable to nicotine-driven invasive cell 
activities. Conversely, MCA and α-BTX, two nAChR 
inhibitors, reversed the nicotine-driven invasive cell activities, 
suggesting that nicotine stimulation of cell activities occurs 
through nAChRs. The head and neck mucous epithelia 
express α3, α5, α7, α9, β2 and β4 nAChRs (16,17). Among 
these nAChR subunits, α7 has been implicated as the most 
powerful nAChR subunit in terms of mediating the 
proliferative effects of nicotine in various cancer cells (18). 
Furthermore, nicotine activates α7 nAChR of keratinocytes in 
the head and neck region (17,39,40). These findings indicate 
that nicotine accelerates cell activity of HNSCC cells via α7 
nAChR. This is consistent with the present in vitro finding that 
MCA and α-BTX inhibited nicotine-increased cell 
proliferation, migration and invasion to the level of the control 
groups. Cetuximab, a chimeric human mouse anti-EGFR 
monoclonal antibody, was the first molecular target drug used 
in head and neck cancer therapy (7,8). In our experiments, 
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nicotine restored the cetuximab-inhibited cell pro-liferation, 
migration and invasion of HNSCC cells. Nicotine is likely to 
attenuate the anti-tumor effect of cetuximab.  However, we 
note here that cetuximab resistance might also arise through 
another mechanism, since nicotine failed to restore the 
cetuximab-inhibited cell activities to the level seen in the 
untreated control groups.  
To date, no study has examined the direct effect of nicotine 
on cetuximab sensitivity, to the best of our knowledge. 
However, a few studies have demonstrated the effect of 
nicotine on anti-EGFR cancer therapy. In non-small cell lung 
cancer, nicotine induces resistance to erlotinib and gefitinib, 
which are EGFR tyrosine kinase inhibitors (23,41). In 
colorectal cancer, cigarette smoking during anticancer 
treatment with a cetuximab-based regimen reduces the 
therapeutic benefit (42). These findings support the present 
hypothesis that nicotine serves a role in cetuximab resis- 
tance.  
In an in vivo experiment, cetuximab inhibited metastasis. 
However, nicotine failed to restore the cetuximab-inhibited 
metastasis. Therefore, the effect of nicotine in metastatic 
HNSCC treated with cetuximab remains unclear, and further 
investigation of this effect is required. In human papillo- 
mavirus-positive oropharyngeal cancer, increased distant 
metastases rates were noted in active smokers vs. never/former 
smokers (22 vs. 5%), and cetuximab-based bio-radio- 
therapy (BRT) vs. cisplatin-based chemoradiotherapy (CRT) 
(23 vs. 5%) (43). Although there was no difference in nodal 
disease extent between CRT and BRT groups in that previous 
study, nicotine and cetuximab may have synergistic negative 
effects in certain types of HNSCC. 
In conclusion, nicotine-nAChR signaling pathways elevated 
the cell activities of HNSCC cells, causing lymph node 
metastasis and serving a role in cetuximab resistance. 
Blockade of nicotine-nAChR signaling may be of clinical 
benefit in cases of advanced HNSCC, especially HNSCC in 
the oral cavity, which is the primary site of exposure to 
nicotine, by inhibiting lymph node metastasis and releasing 
cetuximab resistance. 
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